Brooklyn Investment Group Boosts Stock Holdings in Sanofi (NASDAQ:SNY)

Brooklyn Investment Group lifted its position in Sanofi (NASDAQ:SNY) by 397.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,635 shares of the company’s stock after purchasing an additional 1,306 shares during the period. Brooklyn Investment Group’s holdings in Sanofi were worth $79,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SNY. Northwest Investment Counselors LLC purchased a new stake in shares of Sanofi in the third quarter valued at approximately $29,000. Concord Wealth Partners increased its holdings in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares in the last quarter. Fortitude Family Office LLC raised its position in Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the period. Sunbelt Securities Inc. lifted its holdings in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares in the last quarter. Finally, Versant Capital Management Inc acquired a new stake in shares of Sanofi in the fourth quarter valued at about $54,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Price Performance

Sanofi stock opened at $50.74 on Monday. The company has a fifty day simple moving average of $48.46 and a 200-day simple moving average of $52.11. The firm has a market capitalization of $128.77 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.17 and a beta of 0.57. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.55 EPS. On average, equities analysts anticipate that Sanofi will post 3.94 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.